[1] |
Yu X, Liu P, Liu G, et al. The prevalence of non-tuberculous mycobacterial infections in mainland China: Systematic review and meta-analysis. J Infect, 2016, 73(6):558-567. doi:10.1016/j.jinf.2016.08.020.
pmid: 27717784
|
[2] |
Lin C, Russell C, Soll B, et al. Increasing Prevalence of Nontuberculous Mycobacteria in Respiratory Specimens from US-Affiliated Pacific Island Jurisdictions. Emerg Infect Dis, 2018, 24(3):485-491. doi:10.3201/eid2403.171301.
pmid: 29460734
|
[3] |
Zhou L, Xu D, Liu H, et al. Trends in the Prevalence and Antibiotic Resistance of Non-tuberculous Mycobacteria in Mainland China, 2000—2019: Systematic Review and Meta-Analysis. Front Public Health, 2020, 8:295. doi:10.3389/fpubh.2020.00295.
pmid: 32850570
|
[4] |
Van Ingen J, Obradovic M, Hassan M, et al. Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex-disease burden, unmet needs, and advances in treatment developments. Expert Rev Respir Med, 2021, 15(11):1387-1401. doi:10.1080/17476348.2021.1987891.
|
[5] |
Busatto C, Vianna JS, Da Silva LVJ, et al. Mycobacterium avium: an overview. Tuberculosis (Edinb), 2019, 114:127-134. doi:10.1016/j.tube.2018.12.004.
|
[6] |
Kumar K, Daley CL, Griffith DE, et al. Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments. Eur Respir Rev, 2022, 31(163):210212. doi:10.1183/16000617.0212-2021.
|
[7] |
Li Y, Liu C, Ma A, et al. Identification and drug susceptibility testing of the subspecies of Mycobacterium avium complex clinical isolates in mainland China. J Glob Antimicrob Resist, 2022, 31:90-97. doi:10.1016/j.jgar.2022.05.027.
|
[8] |
Moon SM, Kim SY, Kim DH, et al. Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease. Antimicrob Agents Chemother, 2022, 66(4):e0202721. doi:10.1128/aac.02027-21.
|
[9] |
Zhanel GG, Deng C, Zelenitsky S, et al. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs, 2021, 81(2):233-256. doi:10.1007/s40265-020-01443-4.
pmid: 33247830
|
[10] |
Eraikhuemen N, Julien D, Kelly A, et al. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin. Infect Dis Ther, 2021, 10(1):149-163. doi:10.1007/s40121-020-00378-3.
pmid: 33528794
|
[11] |
Dillon C, Guarascio AJ, Covvey JR. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline. Expert Rev Anti Infect Ther, 2019, 17(1):5-15. doi:10.1080/14787210.2019.1554431.
pmid: 30513017
|
[12] |
Covvey JR, Guarascio AJ. Clinical use of lefamulin: A first-in-class semisynthetic pleuromutilin antibiotic. J Intern Med, 2022, 291(1):51-63. doi:10.1111/joim.13378.
|
[13] |
Salado-Rasmussen K, Nørgaard C, Pedersen TR, et al. In vitro test of the novel antibiotic lefamulin alone and in combination with doxycycline against Mycoplasma genitalium. Antimicrob Agents Chemother, 2025, 69(1):e0134624. doi:10.1128/aac.01346-24.
|
[14] |
Chew KL, Octavia S, Yeoh SF, et al. MIC Values of Iclaprim and Lefamulin against Mycobacterium abscessus Complex. Antimicrob Agents Chemother, 2021, 65(10):e0061921. doi:10.1128/aac.00619-21.
|
[15] |
Van Os W, Zeitlinger M. Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections. J Antimicrob Chemother, 2024, 79(2):443-446. doi:10.1093/jac/dkad401.
pmid: 38174805
|
[16] |
Zeitlinger M, Schwameis R, Burian A, et al. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother, 2016, 71(4):1022-1026. doi:10.1093/jac/dkv442.
pmid: 26747098
|
[17] |
Wicha WW, Prince WT, Lell C, et al. Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing. J Antimicrob Chemother, 2019, 74(Suppl 3):iii19-iii26. doi:10.1093/jac/dkz087.
|
[18] |
File TM, Goldberg L, Das A, et al. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase Ⅲ Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clin Infect Dis, 2019, 69(11):1856-1867. doi:10.1093/cid/ciz090.
|
[19] |
Zheng Y, Ye S, Huang S, et al. Lefamulin Overcomes Acquired Drug Resistance via Regulating Mitochondrial Homeostasis by Targeting ILF 3 in Hepatocellular Carcinoma. Adv Sci (Weinh), 2024, 11(30):e2401789. doi:10.1002/advs.202401789.
|
[20] |
Mccarthy MW. Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin. Clin Pharmacokinet, 2021, 60(11):1387-1394. doi:10.1007/s40262-021-01056-4.
pmid: 34254252
|